Gimv invests in Eurocept, a Dutch healthcare company offering a unique combination of specialty pharma and medical homecare
Today, Gimv and the Gimv Health & Care Fund are announcing their investment in Eurocept, a company selling and marketing specialised medicines and providing medical homecare services. With this substantial investment Gimv acquires a minority interest next to the founder and CEO Mike van Woensel. The financing will be used to further strengthen Eurocept's leading position in the Netherlands and to roll out the business model to neighbouring countries through organic growth and strategic takeovers. The completion of this transaction will be subject to the necessary approval of the Dutch competition authority.
Eurocept is based in the Benelux and offers a unique combination of pharmaceuticals and medical homecare services under one roof. Eurocept Pharmaceuticals is responsible for the registration, marketing, distribution and sale of speciality medicines in the fields of anesthetics, psychiatry, urology, pediatrics and infectious diseases. Eurocept Homecare provides medical specialist homecare and related out-patient medical technology for medicine and food administration. It guarantees that the treatment initiated by the doctor is continued at home in close consultation with this doctor. An innovative care information system and electronic patient and prescription file ensure that all practitioners remain up to date on the patient's medical status to guarantee quality care and better follow-up. The result: hospitals gain time, the patient receives the best possible treatment and doctors always have a full understanding of the effectiveness of the treatment.
The Eurocept Group was established in 2001 and has its head office in Ankeveen, the Netherlands. The group has since grown into a professional organisation with a turnover of EUR 147 million in 2012 and more than 130 employees working in the Benelux and the rest of Europe.
Mike van Woensel on the transaction: "In only a short period of time Eurocept has become a leading player in the Dutch market for specialty pharma and medical home care. Through a number of focused transactions, such as the acquisition of NordMedica (Denmark) in the beginning of this year, we have built up an interesting product portfolio that we also distribute outside the Netherlands. We welcome Gimv as our partner to shape our international growth and to further improve our products and services with the ambition to simplify the relationship between doctor and patient.”
Elderd Land, Partner at Gimv Health & Care: "Eurocept has a specialised portfolio of products and services and a unique IT platform and commercial infrastructure. This integrated approach makes its business model innovative and puts the company in a very good position to respond to current market trends in the treatment of chronically ill patients at home. As a reliable partner for hospitals, pharmaceutical companies and insurers, Eurocept has already developed a considerable customer base in the Netherlands. We are looking forward to doing business with this passionate management team and to supporting its domestic and international expansion."
This is the first deal for the Health & Care Fund, launched by Gimv at the beginning of the year with the Flemish Government as co-sponsor. Health & Care, one of the pillars of the Gimv platform strategy, responds to several major trends in the health sector that represent a huge challenge for our society. The fund gives Gimv the critical mass and fire power to invest in growth companies in the Health & Care Services and Medtech sectors in Belgium, the Netherlands, France and Germany to boost the development of innovative care concepts and the internationalisation of successful business models. The first formal closing of the Fund is foreseen in the first quarter of 2014 with the ambition to raise EUR 200 million.
Bart Diels, Managing Partner at Gimv Health & Care: "This investment fits in perfectly with the strategy of the Health & Care platform. A rising number of chronic diseases, the need for specialised care and the pressure on hospital budgets have resulted in an evolution from in-patient to out-patient care. Eurocept's model can play an important role in this segment, which still has ample scope for growth and consolidation opportunities. We hope that we can support Eurocept in its growth and further transformation into the leading player in this market segment."